TIZANIDINE

Course overview

TIZANIDINE IS A MYOTONOLYTIC AGENT FDA-APPROVED FOR THE MANAGEMENT OF SPASTICITY, WHICH MAY BE CAUSED BY MULTIPLE SCLEROSIS, AN ACQUIRED BRAIN INJURY, OR A SPINAL CORD INJURY. IT HAS ALSO BEEN SHOWN TO BE CLINICALLY EFFECTIVE IN THE MANAGEMENT OF PATIENTS SUFFERING FROM CHRONIC NECK AND LUMBOSACRAL NEURALGIA WITH A MYOFASCIAL COMPONENT TO THEIR PAIN AND REGIONAL MUSCULOSKELETAL PAIN SYNDROMES. ANIMAL STUDIES HAVE SHOWN THAT TIZANIDINE PROVIDES BENEFITS IN THE PERIOPERATIVE PERIOD AND THE MANAGEMENT OF NEUROPATHIC PAIN SUCH AS TRIGEMINAL NEURALGIA, SIMILAR TO THE EFFECTS OF CLONIDINE UNDER SIMILAR CIRCUMSTANCES. IT IS ALSO PRESCRIBED OFF-LABEL FOR MIGRAINE HEADACHES, INSOMNIA, AND AS AN ANTICONVULSANT. TIZANIDINE CAN ALSO BE APPLIED AS PART OF A DETOXIFICATION THERAPY REGIMEN IN PATIENTS EXHIBITING ANALGESIC REBOUND HEADACHES TO ASSIST WITH ANALGESIC WITHDRAWAL. THIS ACTIVITY OUTLINES THE INDICATIONS, MECHANISM OF ACTION, METHODS OF ADMINISTRATION, IMPORTANT ADVERSE EFFECTS, CONTRAINDICATIONS, TOXICITY, AND MONITORING, OF TIZANIDINE SO PROVIDERS CAN DIRECT PATIENT THERAPY WHERE THEY ARE INDICATED AS PART OF THE INTERPROFESSIONAL TEAM.